Global Neuraminidase Inhibitors Drug Market Growth (Status and Outlook) 2020-2025


Sep, 2020 | Report ID: 153504 | 118 | Pharmaceuticals and Healthcare

According to this study, over the next five years the Neuraminidase Inhibitors Drug market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global revenue market share of key companies in Neuraminidase Inhibitors Drug business, shared in Chapter 3.

This report presents a comprehensive overview, market shares, and growth opportunities of Neuraminidase Inhibitors Drug market by product type, application, key manufacturers and key regions and countries.

This study specially analyses the impact of Covid-19 outbreak on the Neuraminidase Inhibitors Drug, covering the supply chain analysis, impact assessment to the Neuraminidase Inhibitors Drug market size growth rate in several scenarios, and the measures to be undertaken by Neuraminidase Inhibitors Drug companies in response to the COVID-19 epidemic.

Segmentation by type: breakdown data from 2015 to 2020 in Section 2.3; and forecast to 2025 in section 10.7.

Oseltamivir

Zanamivir

Peramivir

Laninamivir

Segmentation by application: breakdown data from 2015 to 2020, in Section 2.4; and forecast to 2025 in section 10.8.

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

Others

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.

Roche

GSK

Daiichi Sankyo

Gilead Sciences

...

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key players and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives

To study and analyze the global Neuraminidase Inhibitors Drug market size by key regions/countries, type and application, history data from 2015 to 2019, and forecast to 2025.

To understand the structure of Neuraminidase Inhibitors Drug market by identifying its various subsegments.

Focuses on the key global Neuraminidase Inhibitors Drug players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.

To analyze the Neuraminidase Inhibitors Drug with respect to individual growth trends, future prospects, and their contribution to the total market.

To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

To project the size of Neuraminidase Inhibitors Drug submarkets, with respect to key regions (along with their respective key countries).

To analyze competitive developments such as expansions, agreements, new product launches and acquisitions in the market.

To strategically profile the key players and comprehensively analyze their growth strategies.


Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

1 Scope of the Report

1.1 Market Introduction

1.2 Research Objectives

1.3 Years Considered

1.4 Market Research Methodology

1.5 Economic Indicators

1.6 Currency Considered

2 Executive Summary

2.1 World Market Overview

2.1.1 Global Neuraminidase Inhibitors Drug Market Size 2015-2025

2.1.2 Neuraminidase Inhibitors Drug Market Size CAGR by Region

2.2 Neuraminidase Inhibitors Drug Segment by Type

2.2.1 Oseltamivir

2.2.2 Oseltamivir

2.2.3 Peramivir

2.2.4 Laninamivir

2.3 Neuraminidase Inhibitors Drug Market Size by Type

2.3.1 Global Neuraminidase Inhibitors Drug Market Size Market Share by Type (2015-2020)

2.3.2 Global Neuraminidase Inhibitors Drug Market Size Growth Rate by Type (2015-2020)

2.4 Neuraminidase Inhibitors Drug Segment by Application

2.4.1 Hospital Pharmacy

2.4.2 Retail Pharmacy

2.4.3 Online Pharmacy

2.4.4 Others

2.5 Neuraminidase Inhibitors Drug Market Size by Application

2.5.1 Global Neuraminidase Inhibitors Drug Market Size Market Share by Application (2015-2020)

2.5.2 Global Neuraminidase Inhibitors Drug Market Size Growth Rate by Application (2015-2020)

3 Global Neuraminidase Inhibitors Drug by Players

3.1 Global Neuraminidase Inhibitors Drug Market Size Market Share by Players

3.1.1 Global Neuraminidase Inhibitors Drug Market Size by Players (2018-2020)

3.1.2 Global Neuraminidase Inhibitors Drug Market Size Market Share by Players (2018-2020)

3.2 Global Neuraminidase Inhibitors Drug Key Players Head office and Products Offered

3.3 Market Concentration Rate Analysis

3.3.1 Competition Landscape Analysis

3.3.2 Concentration Ratio (CR3, CR5 and CR10) (2018-2020)

3.4 New Products and Potential Entrants

3.5 Mergers & Acquisitions, Expansion

4 Neuraminidase Inhibitors Drug by Regions

4.1 Neuraminidase Inhibitors Drug Market Size by Regions

4.2 Americas Neuraminidase Inhibitors Drug Market Size Growth

4.3 APAC Neuraminidase Inhibitors Drug Market Size Growth

4.4 Europe Neuraminidase Inhibitors Drug Market Size Growth

4.5 Middle East & Africa Neuraminidase Inhibitors Drug Market Size Growth

5 Americas

5.1 Americas Neuraminidase Inhibitors Drug Market Size by Countries

5.2 Americas Neuraminidase Inhibitors Drug Market Size by Type

5.3 Americas Neuraminidase Inhibitors Drug Market Size by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Key Economic Indicators of Few Americas Countries

6 APAC

6.1 APAC Neuraminidase Inhibitors Drug Market Size by Regions

6.2 APAC Neuraminidase Inhibitors Drug Market Size by Type

6.3 APAC Neuraminidase Inhibitors Drug Market Size by Application

6.4 China

6.5 Japan

6.6 Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 Key Economic Indicators of Few APAC Regions

7 Europe

7.1 Europe Neuraminidase Inhibitors Drug by Countries

7.2 Europe Neuraminidase Inhibitors Drug Market Size by Type

7.3 Europe Neuraminidase Inhibitors Drug Market Size by Application

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

7.9 Key Economic Indicators of Few Europe Countries

8 Middle East & Africa

8.1 Middle East & Africa Neuraminidase Inhibitors Drug by Countries

8.2 Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Type

8.3 Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Application

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 Market Drivers, Challenges and Trends

9.1 Market Drivers and Impact

9.1.1 Growing Demand from Key Regions

9.1.2 Growing Demand from Key Applications and Potential Industries

9.2 Market Challenges and Impact

9.3 Market Trends

10 Global Neuraminidase Inhibitors Drug Market Forecast

10.1 Global Neuraminidase Inhibitors Drug Market Size Forecast (2021-2025)

10.2 Global Neuraminidase Inhibitors Drug Forecast by Regions

10.2.1 Global Neuraminidase Inhibitors Drug Forecast by Regions (2021-2025)

10.2.2 Americas Market Forecast

10.2.3 APAC Market Forecast

10.2.4 Europe Market Forecast

10.2.5 Middle East & Africa Market Forecast

10.3 Americas Forecast by Countries

10.3.1 United States Market Forecast

10.3.2 Canada Market Forecast

10.3.3 Mexico Market Forecast

10.3.4 Brazil Market Forecast

10.4 APAC Forecast by Countries

10.4.1 China Market Forecast

10.4.2 Japan Market Forecast

10.4.3 Korea Market Forecast

10.4.4 Southeast Asia Market Forecast

10.4.5 India Market Forecast

10.4.6 Australia Market Forecast

10.5 Europe Forecast by Countries

10.5.1 Germany Market Forecast

10.5.2 France Market Forecast

10.5.3 UK Market Forecast

10.5.4 Italy Market Forecast

10.5.5 Russia Market Forecast

10.5.6 Spain Market Forecast

10.6 Middle East & Africa Forecast by Countries

10.6.1 Egypt Market Forecast

10.6.2 South Africa Market Forecast

10.6.3 Israel Market Forecast

10.6.4 Turkey Market Forecast

10.6.5 GCC Countries Market Forecast

10.7 Global Neuraminidase Inhibitors Drug Forecast by Type

10.8 Global Neuraminidase Inhibitors Drug Forecast by Application

11 Key Players Analysis

11.1 Roche

11.1.1 Company Details

11.1.2 Neuraminidase Inhibitors Drug Product Offered

11.1.3 Roche Neuraminidase Inhibitors Drug Revenue, Gross Margin and Market Share (2018-2020)

11.1.4 Main Business Overview

11.1.5 Roche News

11.2 GSK

11.2.1 Company Details

11.2.2 Neuraminidase Inhibitors Drug Product Offered

11.2.3 GSK Neuraminidase Inhibitors Drug Revenue, Gross Margin and Market Share (2018-2020)

11.2.4 Main Business Overview

11.2.5 GSK News

11.3 Daiichi Sankyo

11.3.1 Company Details

11.3.2 Neuraminidase Inhibitors Drug Product Offered

11.3.3 Daiichi Sankyo Neuraminidase Inhibitors Drug Revenue, Gross Margin and Market Share (2018-2020)

11.3.4 Main Business Overview

11.3.5 Daiichi Sankyo News

11.4 Gilead Sciences

11.4.1 Company Details

11.4.2 Neuraminidase Inhibitors Drug Product Offered

11.4.3 Gilead Sciences Neuraminidase Inhibitors Drug Revenue, Gross Margin and Market Share (2018-2020)

11.4.4 Main Business Overview

11.4.5 Gilead Sciences News

...

12 Research Findings and Conclusion

List of Tables

Table 1. Research Methodology

Table 2. Data Source

Table 3. Neuraminidase Inhibitors Drug Market Size CAGR by Region 2015-2025 ($ Millions)

Table 4. Major Players of Oseltamivir

Table 5. Major Players of Zanamivir

Table 6. Major Players of Peramivir

Table 7. Major Players of Laninamivir

Table 8. Neuraminidase Inhibitors Drug Market Size by Type (2014-2019) ($ Millions)

Table 9. Global Neuraminidase Inhibitors Drug Market Size Market Share by Type (2015-2020)

Table 10. Global Neuraminidase Inhibitors Drug Market Size by Application (2015-2020) ($ Millions)

Table 11. Global Neuraminidase Inhibitors Drug Market Size Market Share by Application (2015-2020)

Table 12. Global Neuraminidase Inhibitors Drug Revenue by Players (2018-2020) ($ Millions)

Table 13. Global Neuraminidase Inhibitors Drug Revenue Market Share by Players (2018-2020)

Table 14. Global Neuraminidase Inhibitors Drug Key Players Head office and Products Offered

Table 15. Neuraminidase Inhibitors Drug Concentration Ratio (CR3, CR5 and CR10) (2018-2020)

Table 16. New Products and Potential Entrants

Table 17. Mergers & Acquisitions, Expansion

Table 18. Global Neuraminidase Inhibitors Drug Market Size by Regions 2015-2020 ($ Millions)

Table 19. Global Neuraminidase Inhibitors Drug Market Size Market Share by Regions 2015-2020

Table 20. Americas Neuraminidase Inhibitors Drug Market Size by Countries (2015-2020) ($ Millions)

Table 21. Americas Neuraminidase Inhibitors Drug Market Size Market Share by Countries (2015-2020)

Table 22. Americas Neuraminidase Inhibitors Drug Market Size by Type (2015-2020) ($ Millions)

Table 23. Americas Neuraminidase Inhibitors Drug Market Size Market Share by Type (2015-2020)

Table 24. Americas Neuraminidase Inhibitors Drug Market Size by Application (2015-2020) ($ Millions)

Table 25. Americas Neuraminidase Inhibitors Drug Market Size Market Share by Application (2015-2020)

Table 26. APAC Neuraminidase Inhibitors Drug Market Size by Regions (2015-2020) ($ Millions)

Table 27. APAC Neuraminidase Inhibitors Drug Market Size Market Share by Regions (2015-2020)

Table 28. APAC Neuraminidase Inhibitors Drug Market Size by Type (2015-2020) ($ Millions)

Table 29. APAC Neuraminidase Inhibitors Drug Market Size Market Share by Type (2015-2020)

Table 30. APAC Neuraminidase Inhibitors Drug Market Size by Application (2015-2020) ($ Millions)

Table 31. APAC Neuraminidase Inhibitors Drug Market Size Market Share by Application (2015-2020)

Table 32. Europe Neuraminidase Inhibitors Drug Market Size by Countries (2015-2020) ($ Millions)

Table 33. Europe Neuraminidase Inhibitors Drug Market Size Market Share by Countries (2015-2020)

Table 34. Europe Neuraminidase Inhibitors Drug Market Size by Type (2015-2020) ($ Millions)

Table 35. Europe Neuraminidase Inhibitors Drug Market Size Market Share by Type (2015-2020)

Table 36. Europe Neuraminidase Inhibitors Drug Market Size by Application (2015-2020) ($ Millions)

Table 37. Europe Neuraminidase Inhibitors Drug Market Size Market Share by Application (2015-2020)

Table 38. Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Countries (2015-2020) ($ Millions)

Table 39. Middle East & Africa Neuraminidase Inhibitors Drug Market Size Market Share by Countries (2015-2020)

Table 40. Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Type (2015-2020) ($ Millions)

Table 41. Middle East & Africa Neuraminidase Inhibitors Drug Market Size Market Share by Type (2015-2020)

Table 42. Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Application (2015-2020) ($ Millions)

Table 43. Middle East & Africa Neuraminidase Inhibitors Drug Market Size Market Share by Application (2015-2020)

Table 44. Key and Potential Regions of Neuraminidase Inhibitors Drug

Table 45. Key Application and Potential Industries of Neuraminidase Inhibitors Drug

Table 46. Key Challenges of Neuraminidase Inhibitors Drug

Table 47. Key Trends of Neuraminidase Inhibitors Drug

Table 48. Global Neuraminidase Inhibitors Drug Market Size Forecast by Regions (2021-2025) ($ Millions)

Table 49. Global Neuraminidase Inhibitors Drug Market Size Market Share Forecast by Regions

Table 50. Global Neuraminidase Inhibitors Drug Market Size Forecast by Type (2021-2025) ($ Millions)

Table 51. Global Neuraminidase Inhibitors Drug Market Size Market Share Forecast by Type (2021-2025)

Table 52. Global Neuraminidase Inhibitors Drug Market Size Forecast by Application (2021-2025) ($ Millions)

Table 53. Global Neuraminidase Inhibitors Drug Market Size Market Share Forecast by Application (2021-2025)

Table 54. Roche Details, Company Total Revenue (in $ million), Head Office, Neuraminidase Inhibitors Drug Major Market Areas and Its Competitors

Table 55. Roche Neuraminidase Inhibitors Drug Product Offered

Table 56. Roche Neuraminidase Inhibitors Drug Revenue and Gross Margin (2018-2020E)

Table 57. Roche Main Business

Table 58. Roche Latest Developments

Table 59. GSK Details, Company Total Revenue (in $ million), Head Office, Neuraminidase Inhibitors Drug Major Market Areas and Its Competitors

Table 60. GSK Neuraminidase Inhibitors Drug Product Offered

Table 61. GSK Main Business

Table 62. GSK Neuraminidase Inhibitors Drug Revenue and Gross Margin (2018-2020E)

Table 63. GSK Latest Developments

Table 64. Daiichi Sankyo Details, Company Total Revenue (in $ million), Head Office, Neuraminidase Inhibitors Drug Major Market Areas and Its Competitors

Table 65. Daiichi Sankyo Neuraminidase Inhibitors Drug Product Offered

Table 66. Daiichi Sankyo Main Business

Table 67. Daiichi Sankyo Neuraminidase Inhibitors Drug Revenue and Gross Margin (2018-2020E)

Table 68. Daiichi Sankyo Latest Developments

Table 69. Gilead Sciences Details, Company Total Revenue (in $ million), Head Office, Neuraminidase Inhibitors Drug Major Market Areas and Its Competitors

Table 70. Gilead Sciences Neuraminidase Inhibitors Drug Product Offered

Table 71. Gilead Sciences Main Business

Table 72. Gilead Sciences Neuraminidase Inhibitors Drug Revenue and Gross Margin (2018-2020E)

Table 73. Gilead Sciences Latest Developments

List of Figures

Figure 1. Neuraminidase Inhibitors Drug Report Years Considered

Figure 2. Market Research Methodology

Figure 3. Global Neuraminidase Inhibitors Drug Market Size Growth Rate 2015-2025 ($ Millions)

Figure 4. Global Neuraminidase Inhibitors Drug Market Size Market Share by Type (2015-2020)

Figure 5. Global Oseltamivir Market Size Growth Rate

Figure 6. Global Zanamivir Market Size Growth Rate

Figure 7. Global Peramivir Market Size Growth Rate

Figure 8. Global Laninamivir Market Size Growth Rate

Figure 9. Neuraminidase Inhibitors Drug in Hospital Pharmacy

Figure 10. Global Neuraminidase Inhibitors Drug Market: Hospital Pharmacy (2015-2020) ($ Millions)

Figure 11. Neuraminidase Inhibitors Drug in Retail Pharmacy

Figure 12. Global Neuraminidase Inhibitors Drug Market: Retail Pharmacy (2015-2020) ($ Millions)

Figure 13. Neuraminidase Inhibitors Drug in Online Pharmacy

Figure 14. Global Neuraminidase Inhibitors Drug Market: Online Pharmacy (2015-2020) ($ Millions)

Figure 15. Global Online Pharmacy YoY Growth ($ Millions)

Figure 16. Neuraminidase Inhibitors Drug in Others

Figure 17. Global Neuraminidase Inhibitors Drug Market: Others (2015-2020) ($ Millions)

Figure 18. Global Others YoY Growth ($ Millions)

Figure 19. Global Neuraminidase Inhibitors Drug Market Size Market Share by Application in 2019

Figure 20. Global Neuraminidase Inhibitors Drug Market Size Market Share by Regions 2015-2020

Figure 21. Americas Neuraminidase Inhibitors Drug Market Size 2015-2020 ($ Millions)

Figure 22. APAC Neuraminidase Inhibitors Drug Market Size 2015-2020 ($ Millions)

Figure 23. Europe Neuraminidase Inhibitors Drug Market Size 2015-2020 ($ Millions)

Figure 24. Middle East & Africa Neuraminidase Inhibitors Drug Market Size 2015-2020 ($ Millions)

Figure 25. Americas Neuraminidase Inhibitors Drug Market Size Market Share by Countries in 2019

Figure 26. Americas Neuraminidase Inhibitors Drug Market Size Market Share by Type in 2019

Figure 27. Americas Neuraminidase Inhibitors Drug Market Size Market Share by Application in 2019

Figure 28. United States Neuraminidase Inhibitors Drug Market Size Growth 2015-2020 ($ Millions)

Figure 29. Canada Neuraminidase Inhibitors Drug Market Size Growth 2015-2020 ($ Millions)

Figure 30. Mexico Neuraminidase Inhibitors Drug Market Size Growth 2015-2020 ($ Millions)

Figure 31. APAC Neuraminidase Inhibitors Drug Market Size Market Share by Regions in 2019

Figure 32. APAC Neuraminidase Inhibitors Drug Market Size Market Share by Type in 2019

Figure 33. APAC Neuraminidase Inhibitors Drug Market Size Market Share by Application in 2019

Figure 34. China Neuraminidase Inhibitors Drug Market Size Growth 2015-2020 ($ Millions)

Figure 35. Japan Neuraminidase Inhibitors Drug Market Size Growth 2015-2020 ($ Millions)

Figure 36. Korea Neuraminidase Inhibitors Drug Market Size Growth 2015-2020 ($ Millions)

Figure 37. Southeast Asia Neuraminidase Inhibitors Drug Market Size Growth 2015-2020 ($ Millions)

Figure 38. India Neuraminidase Inhibitors Drug Market Size Growth 2015-2020 ($ Millions)

Figure 39. Australia Neuraminidase Inhibitors Drug Market Size Growth 2015-2020 ($ Millions)

Figure 40. Europe Neuraminidase Inhibitors Drug Market Size Market Share by Countries in 2019

Figure 41. Europe Neuraminidase Inhibitors Drug Market Size Market Share by Type in 2019

Figure 42. Europe Neuraminidase Inhibitors Drug Market Size Market Share by Application in 2019

Figure 43. Germany Neuraminidase Inhibitors Drug Market Size Growth 2015-2020 ($ Millions)

Figure 44. France Neuraminidase Inhibitors Drug Market Size Growth 2015-2020 ($ Millions)

Figure 45. UK Neuraminidase Inhibitors Drug Market Size Growth 2015-2020 ($ Millions)

Figure 46. Italy Neuraminidase Inhibitors Drug Market Size Growth 2015-2020 ($ Millions)

Figure 47. Russia Neuraminidase Inhibitors Drug Market Size Growth 2015-2020 ($ Millions)

Figure 48. Spain Neuraminidase Inhibitors Drug Market Size Growth 2015-2020 ($ Millions)

Figure 49. Middle East & Africa Neuraminidase Inhibitors Drug Market Size Market Share by Countries in 2019

Figure 50. Middle East & Africa Neuraminidase Inhibitors Drug Market Size Market Share by Type in 2019

Figure 51. Middle East & Africa Neuraminidase Inhibitors Drug Market Size Market Share by Application in 2019

Figure 52. Egypt Neuraminidase Inhibitors Drug Market Size Growth 2015-2020 ($ Millions)

Figure 53. South Africa Neuraminidase Inhibitors Drug Market Size Growth 2015-2020 ($ Millions)

Figure 54. Israel Neuraminidase Inhibitors Drug Market Size Growth 2015-2020 ($ Millions)

Figure 55. Turkey Neuraminidase Inhibitors Drug Market Size Growth 2015-2020 ($ Millions)

Figure 56. GCC Countries Neuraminidase Inhibitors Drug Market Size Growth 2015-2020 ($ Millions)

Figure 57. Global Neuraminidase Inhibitors Drug arket Size Forecast (2021-2025) ($ Millions)

Figure 58. Americas Neuraminidase Inhibitors Drug Market Size 2021-2025 ($ Millions)

Figure 59. APAC Neuraminidase Inhibitors Drug Market Size 2021-2025 ($ Millions)

Figure 60. Europe Neuraminidase Inhibitors Drug Market Size 2021-2025 ($ Millions)

Figure 61. Middle East & Africa Neuraminidase Inhibitors Drug Market Size 2021-2025 ($ Millions)

Figure 62. United States Neuraminidase Inhibitors Drug Market Size 2021-2025 ($ Millions)

Figure 63. Canada Neuraminidase Inhibitors Drug Market Size 2021-2025 ($ Millions)

Figure 64. Mexico Neuraminidase Inhibitors Drug Market Size 2021-2025 ($ Millions)

Figure 65. Brazil Neuraminidase Inhibitors Drug Market Size 2021-2025 ($ Millions)

Figure 66. China Neuraminidase Inhibitors Drug Market Size 2021-2025 ($ Millions)

Figure 67. Japan Neuraminidase Inhibitors Drug Market Size 2021-2025 ($ Millions)

Figure 68. Korea Neuraminidase Inhibitors Drug Market Size 2021-2025 ($ Millions)

Figure 69. Southeast Asia Neuraminidase Inhibitors Drug Market Size 2021-2025 ($ Millions)

Figure 70. India Neuraminidase Inhibitors Drug Market Size 2021-2025 ($ Millions)

Figure 71. Australia Neuraminidase Inhibitors Drug Market Size 2021-2025 ($ Millions)

Figure 72. Germany Neuraminidase Inhibitors Drug Market Size 2021-2025 ($ Millions)

Figure 73. France Neuraminidase Inhibitors Drug Market Size 2021-2025 ($ Millions)

Figure 74. UK Neuraminidase Inhibitors Drug Market Size 2021-2025 ($ Millions)

Figure 75. Italy Neuraminidase Inhibitors Drug Market Size 2021-2025 ($ Millions)

Figure 76. Russia Neuraminidase Inhibitors Drug Market Size 2021-2025 ($ Millions)

Figure 77. Spain Neuraminidase Inhibitors Drug Market Size 2021-2025 ($ Millions)

Figure 78. Egypt Neuraminidase Inhibitors Drug Market Size 2021-2025 ($ Millions)

Figure 79. South Africa Neuraminidase Inhibitors Drug Market Size 2021-2025 ($ Millions)

Figure 80. Israel Neuraminidase Inhibitors Drug Market Size 2021-2025 ($ Millions)

Figure 81. Turkey Neuraminidase Inhibitors Drug Market Size 2021-2025 ($ Millions)

Figure 82. GCC Countries Neuraminidase Inhibitors Drug Market Size 2021-2025 ($ Millions)

Sample Request is not available